Phase 2 N=16 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) Response — 14 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=169 Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C
Hepatitis C, Chronic
Primary: Relapse Rate — 30.5; 37.7; 35.1 percentage of participants — p=0.72
Phase 2 N=311 Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295)
Asthma · Common Cold · Picornavirus Infection
Primary: Percentage of Participants With Rhinovirus PCR-Positive Colds — 2.6; 2.5 percentage of participants — p=0.973
Phase 2 N=20 A Phase 2 Study Of PF-00232798 In HIV Positive Patients
HIV
Primary: Change From Baseline in Log 10-transformed Human Immunodeficiency Virus (HIV) Viral Load at Day 11 — 4.692; 4.338; 4.306; 4.483 log10 copies/mL
Phase 2 N=59 Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
Acute Myeloid Leukemia
Primary: Overall Response: Number of Participants With Complete Remission or Complete Remission Without Platelet Recovery — 42; 3 participants
Phase 2 N=35 Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults
Infection, Human Immunodeficiency Virus
Primary: Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 — 0.05; -1.51; -2.03; -2.46 Log10 copies/milliliter (log10…
Phase 2 N=10 Tailored Computerized Mobilization of the Cervical Spine Utilizing the Occiflex Device for the Treatment of Chronic Neck Pain
Neck Pain
Primary: Occiflex Device Safety — 26 Number of adverse effects
Phase 2 N=256 A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
Skin and Subcutaneous Tissue Bacterial Infections
Primary: Investigator's Assessment of Clinical Response in the ITT (Intent-to-treat) Population at Follow-up — 57; 50; 53 Participants
Phase 2 N=60 Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Recurrent Central Nervous System Neoplasm
Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients
Phase 2 N=14 Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder
OCD
Primary: Yale Brown Obsessive Compulsive Scale — 24.79; 12.71; 16.00; 15.36 units on a scale — p=0.0002
Phase 2 N=368 A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
Human Immunodeficiency Virus Type 1
Primary: Number of Participants With Virologic Response at Week 48 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR)…
Phase 2 N=92 Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change in International Prostate Symptom Scale (IPSS) of Lower Urinary Tract Symptoms From Baseline to 3 Months (Total Score at 3 Months Minus Total Score at Baseline)…
Phase 2 N=88 A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
Myelofibrosis With Myeloid Metaplasia · Myeloid Metaplasia · Myelofibrosis
Primary: Percentage of Participants With a Clinical Response Within the First 6 Cycles of Treatment — 55.0; 23.5; 21.1; 47.6 percentage of participants — p=0.092
Phase 2 N=30 Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants
Multiple Myeloma · Plasma Cell Leukemia
Primary: Overall Survival (OS) — 40 months
Phase 2 N=5 Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery
Scar Formation
Primary: Photography- Independent Scar Assessment Panel